Drug Profile
Research programme: chimeric antigen receptor T cell therapeutics - MabVax/MSKCC
Alternative Names: CAR T-cell therapeutics - MabVax/MSKCC; CART cell therapies - MabVax/MSKCCLatest Information Update: 28 Oct 2018
Price :
$50
*
At a glance
- Originator MabVax Therapeutics; Memorial Sloan-Kettering Cancer Center
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for research development in Solid-tumours in USA (Parenteral)
- 06 Mar 2018 Juno Therapeutics has been acquired by Celgene Corporation
- 31 May 2017 MabVax Therapeutics enters into a research agreement with Memorial Sloan Kettering Cancer Center for Pancreatic cancer, Small cell lung cancer and other Solid tumours